open access

Vol 73, Supp. VI (2015)
Reviews
Published online: 2015-11-25
Get Citation

XANTUS, a prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation

Marek Postuła, Dariusz Kosior
DOI: 10.5603/KP.2015.0220

open access

Vol 73, Supp. VI (2015)
Reviews
Published online: 2015-11-25

Abstract

XANTUS is the first large, international prospective study to describe rivaroxaban use in a broad patient population with non-valvular atrial fibrillation. Out of 6784 patients, over 96% patients receiving rivaroxaban did not experience any of the outcomes of stroke/systemic embolism, treatment-emergent major bleeding or all-cause death. In XANTUS, rivaroxaban demonstrated low rates of stroke/ systemic embolism and major bleeding, including intracranial and gastrointestinal bleeding. Treatment persistence and patient satisfaction were high, namely 80% of patients remained on rivaroxaban and 75% reported they were satisfied with their treatment at one year.

Abstract

XANTUS is the first large, international prospective study to describe rivaroxaban use in a broad patient population with non-valvular atrial fibrillation. Out of 6784 patients, over 96% patients receiving rivaroxaban did not experience any of the outcomes of stroke/systemic embolism, treatment-emergent major bleeding or all-cause death. In XANTUS, rivaroxaban demonstrated low rates of stroke/ systemic embolism and major bleeding, including intracranial and gastrointestinal bleeding. Treatment persistence and patient satisfaction were high, namely 80% of patients remained on rivaroxaban and 75% reported they were satisfied with their treatment at one year.

Get Citation

Keywords

anticoagulants, atrial fibrillation, rivaroxaban, stroke, thromboembolism

About this article
Title

XANTUS, a prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 73, Supp. VI (2015)

Pages

71-75

Published online

2015-11-25

Page views

293

Article views/downloads

725

DOI

10.5603/KP.2015.0220

Keywords

anticoagulants
atrial fibrillation
rivaroxaban
stroke
thromboembolism

Authors

Marek Postuła
Dariusz Kosior

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Sp. z o.o. VM Group Sp.k., ul. Świętokrzyska 73 , 80–180 Gdańsk, Poland

phone:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl